β-adrenergic pathways in human heart failure

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 1, 2007, Pages 119-124

  Sucharov, Carmen C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

adrenergic; CaMKII; cAMP; Fetal gene program; PDE3; Phospholamban; PKA PP1; Receptors

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; ENOXIMONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE INHIBITOR;

CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG TARGETING; ENZYME ACTIVATION; HEART FAILURE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REVIEW; TREATMENT OUTCOME;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, DILATED; CYCLIC AMP; DISEASE PROGRESSION; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCYTES, CARDIAC; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 33846554749     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.1.119     Document Type: Review

References (53)

1. Devereux RB, Roman MJ. Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res. 22(1), 1-9 (1999).
2. Iwanaga Y, Kihara Y, Inagaki K et al. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 104(5), 606-612 (2001).
3. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J. Am. Coll. Cardiol. 20(7), 1594-1598 (1992).
4. Bonow RO. Aortic Regurgitation. Curr. Treat. Options Cardiovasc. Med. 2(2), 125-132 (2000).
5. Bristow MR. Mechanism of action of β-blocking agents in heart failure. Am. J. Cardiol. 80(11A), 26L-40L (1997).
6. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am. J. Cardiol. 80(11A), 7L-14L (1997).
7. Lowes BD, Gilbert EM, Abraham WT et al. Myocardial gene expression in dilated cardiomyopathy treated with β-blocking agents. N. Engl. J. Med. 346(18), 1357-1365 (2002).
8. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: β-adrenergic receptors - alterations in signal transduction and pharmacogenomics in heart failure. Nat. Clin. Pract. Cardiovasc. Med. 2(9), 475-483 (2005).
9. Mongillo M, Tocchetti CG, Terrin A et al. Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ. Res. 98(2), 226-234 (2006).
10. Morisco C, Zebrowski DC, Vatner DE, Vatner SF, Sadoshima J. β-adrenergic cardiac hypertrophy is mediated primarily by the β(1)-subtype in the rat heart. J. Mol. Cell. Cardiol. 33(3), 561-573 (2001).
11. Wallukat G. The β-adrenergic receptors. Herz 27(7), 683-690 (2002).
12. Rapacciuolo A, Suvarna S, Barki-Harrington L et al. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates β-1 adrenergic receptor endocytosis through different pathways. J. Biol. Chem. 278(37), 35403-35411 (2003).
13. Port JD BM. Adrenergic Receptor Coupling and uncoupling in heart failure. In: Richard A. Walsh (Ed.). Molecular Mechanism for Cardiac Hypertrophy and Failure, 323-340.
14. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc. Res. 61(1), 87-93 (2004).
15. Movsesian MA, Bristow MR. Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr. Top. Dev. Biol. 68, 25-48 (2005).
16. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic signaling in heart failure? Circ. Res. 93(10), 896-906 (2003).
17. Movsesian MA. β-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate. J. Am. Coll. Cardiol. 34(2), 318-324 (1999).
18. Cleland JG, Coletta AP, Lammiman M et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur. J. Heart Fail. 7(6), 1070-1075 (2005).
19. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog. Nucleic Acid Res. Mol. Biol.66, 241-277 (2001).
20. Ding B, Abe J, Wei H et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: Implication in heart failure. Circulation 111(19), 2469-2476 (2005).
21. Ding B, Abe J, Wei H et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc. Natl Acad. Sci. USA 102(41), 14771-14776 (2005).
22. Fitzgerald LR, Li Z, Machida CA, Fishman PH, Duman RS. Adrenergic regulation of ICER (inducible cyclic AMP early repressor) and β1-adrenergic receptor gene expression in C6 glioma cells. J. Neurochem. 67(2), 490-497 (1996).
23. Simmerman HK, Jones LR. Phospholamban: Protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. 78(4), 921-947 (1998).
24. 2+/calmodulin kinase signaling pathway. Circ. Res. 95(8), 798-806 (2004).
25. 2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc. Res. 42(1), 254-261 (1999).
26. 2+) uptake in human failing left ventricular myocardium. J. Heart Lung Transplant 21(3), 366-373 (2002).
27. Neumann J, Eschenhagen T, Jones LR et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell. Cardiol. 29(1), 265-272 (1997).
28. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J. Physiol. Heart Circ. Physiol. 285(6), H2373-H2381 (2003).
29. Kirchhefer U, Baba HA, Boknik P et al. Enhanced cardiac function in mice overexpressing protein phosphatase Inhibitor-2. Cardiovasc. Res. 68(1), 98-108 (2005).
30. Yamada M, Ikeda Y, Yano M et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. Faseb J. 20(8), 1197-1199 (2006).
31. Wang W, Wang S, Zhu W, Xiao R, Cheng H. Long-term β1-adrenergic modulation of cardiac contractility via calmodulin kinase II signaling pathway. Supplement to Circulation 108(17), 1 (2003).
32. 2+/calmodulin kinase II. J. Clin. Invest. 111(5), 617-625 (2003).
33. Zhang R, Khoo MS, Wu Y et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11(4), 409-417 (2005).
34. Braun AP, Schulman H. The multifunctional calcium/calmodulin-dependent protein kinase: From form to a function. Annu. Rev. Physiol. 57, 417-445 (1995).
35. Griffith LC. Regulation of calcium/calmodulin-dependent protein kinase II activation by intramolecular and intermolecular interactions. J. Neurosci. 24(39), 8394-8398 (2004).
36. Zhang T, Maier LS, Dalton ND et al. The δC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res. 92(8), 912-9 (2003).
37. 2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J. Biol. Chem. 277(2), 1261-7 (2002).
38. 2+/ calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ. Res. 84(6), 713-721 (1999).
39. Witcher DR, Kovacs RJ, Schulman H, Cefali DC, Jones LR. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J. Biol. Chem. 266(17), 11144-11152 (1991).
40. Hain J, Onoue H, Mayrleitner M, Fleischer S, Schindler H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J. Biol. Chem. 270(5), 2074-2081 (1995).
41. Dzhura I, Wu Y, Colbran RJ, Balser JR, Anderson ME. Calmodulin kinase determines calcium-dependent facilitation of L-type calcium channels. Nat. Cell Biol. 2(3), 173-177 (2000).
42. Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J. Biol. Chem. 261(28), 13333-13341 (1986).
43. Le Peuch CJ, Haiech J, Demaille JG. Concerted regulation of cardiac sarcoplasmic reticulum calcium transport by cyclic adenosine monophosphate dependent and calcium-calmodulin-dependent phosphorylations. Biochemistry 18 (23), 5150-5157 (1979).
44. Maier LS, Bers DM. Calcium, calmodulin, and calcium-calmodulin kinase II: Heartbeat to heartbeat and beyond. J. Mol. Cell. Cardiol. 34(8), 919-939 (2002).
45. Zhang T, Miyamoto S, Brown JH. Cardiomyocyte calcium and calcium/ calmodulin-dependent protein kinase II: Friends or foes? Recent Prog. Horm. Res. 59, 141-168 (2004).
46. 2+/calmodulin-dependent protein kinase. J. Biol. Chem. 268(12), 8394-8397 (1993).
47. 2+/calmodulin-dependent phosphorylation or by interaction with phospholamban. J. Biol. Chem. 271(24), 14206-14213 (1996).
48. 2+/calmodulin-dependent protein kinase II. Differential expression in rat brain and aorta. J. Biol. Chem. 268(19), 14443-9 (1993).
49. Lompre AM, Schwartz K, d'Albis A, Lacombe G, Van Thiem N, Swynghedauw B. Myosin isoenzyme redistribution in chronic heart overload. Nature 282(5734), 105-107 (1979).
50. Boluyt MO, Long X, Eschenhagen T et al. Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am. J. Physiol. 269(2 Pt 2), H638-H647 (1995).
51. Rothermel BA, McKinsey TA, Vega RB et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 98(6), 3328-3333 (2001).
52. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94(9), 2285-2296 (1996).
53. Sucharov CC, Mariner PD, Nunley KR, Long CS, Leinwand LA, Bristow MR. A {beta}1-adrenergic receptor, CaM Kinase II dependent pathway mediates cardiac myocyte fetal gene induction. Am. J. Physiol. Heart Circ. Physiol. 291(3), H1299-H308 2006.